Study
| Multicentre, open-label, phase 1–2 study (MonumenTAL-1) |
| Relapsed/refractory multiple myeloma pts with ≥3 prior lines of therapy |
| Talquetamab 0.4 mg/kg weekly or 0.8 mg/kg every 2 wks subcutaneously |
Efficacy
| ORR: 74% vs. 69% vs. 67% (0.4 mg/kg weekly vs. 0.8 mg/kg q2wks vs. prior TCR) |
| mPFS: 7.5 mos vs. 11.2 mos vs. 7.7 mos |
| 12-mo OS: 76% vs. 77% vs. 74% |
| mDoR: 11.1 mos vs. 16.9 mos |
| 12-mo DoR: 56% (prior TCR group) |
Safety
| Grade ≥3 AEs: Neutropenia (31% vs. 21% vs. 47%), anaemia (31% vs. 26% vs. 27%), lymphopenia (26% vs. 26% vs. 17%) |
| Infections (any grade): 59% vs. 68% vs. 76%; Grade ≥3: 20% vs. 18% vs. 26% |
| Cytokine release syndrome: 79% vs. 75% vs. 73% |
| Treatment-related discontinuations: 5% vs. 9% vs. 5% |
| Treatment-related deaths: 0 |
Lancet Haematol 2025;12:e269–81
http://doi.org/10.1016/S2352-3026(24)00385-5
Reviewed by Ulas D. Bayraktar, MD on Apr 7, 2025
